The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • A drop of blood can detect Alzheimer’s – international award

    The 2026 Jeffrey L. Morby Prize has been awarded to researchers from Lund University and Washington University for a...

    Read more...

  • New blood biomarker reduces the risk of misdiagnosing Alzheimer’s disease.

    The new blood tests for diagnosing Alzheimer’s disease are providing increasingly better opportunities for early diagnosis, but one challenge...

    Read more...
More news...

X posts

BioFINDER Follow 714 1,533

biofinder_study
biofinder_study avatar BioFINDER @biofinder_study ·
2 Jun 2061777988442554513

New paper in @GreenJournal! We investigated whether future AD dementia can be predicted in individuals with subjective cognitive decline. We found that plasma p-tau217, cognitive testing, and APOE ε4 status accurately identify those at highest risk. https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000214983

biofinder_study avatar BioFINDER @biofinder_study ·
2 Jun 2061777990468419625

This study was led by María Rivera Sánchez. A huge thanks to all co-authors: @SEMastenbroek, @NiklasMattsson4, @DaniellevWe, @EStomrud, @SebastianPalmqv, @RikOssenkoppele

biofinder_study avatar BioFINDER @biofinder_study ·
27 May 2059554507499962740

New publication in JAMA Neurology! 🧠
In this study, led by @gesalbla, we developed and validated a plasma-based biological staging model for Alzheimer’s disease using two blood biomarkers: %p-tau217 and eMTBR-tau243.

Image for twitter card

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease tha...

jamanetwork.com
biofinder_study avatar BioFINDER @biofinder_study ·
27 May 2059554520737145137

This supports the potential of blood-based biological staging as scalable alternative to PET imaging for AD characterization. This approach may improve participant stratification for clinical trials and facilitate broader implementation of biological staging in clinical practice.

biofinder_study avatar BioFINDER @biofinder_study ·
27 May 2059554522452688914

A huge thank you to all co-authors and collaborators for their incredible work on this project: @KantaHorie, @SuzanneESchind1, @A_OrdunaDolado, @tlsmit1, @BrianGordon81, @NiklasMattsson4, @SebastianPalmqv, @_JakeVogel_ @RandallBateman3, @RikOssenkoppele, and all not on X.

biofinder_study avatar BioFINDER @biofinder_study ·
15 May 2055266593441988615

New paper in Nature Aging led by PhD student @LuLina000147323! We mapped how APOE ε4 and APOE ε2 shape molecular changes in blood and cerebrospinal fluid across Alzheimer’s disease.

Image for twitter card

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease

Nature Aging - Apolipoprotein E (APOE) is the strongest genetic influence in Alzheimer’s disease (AD). Compared to ...

www.nature.com
biofinder_study avatar BioFINDER @biofinder_study ·
15 May 2055266595241415114

Using large-scale proteomics across multiple cohorts, we found that APOE ε4 and APOE ε2 have largely distinct protein signatures. Many changes appeared even before detectable Aβ pathology, suggesting that APOE-related molecular alterations may begin long before dementia develops.

biofinder_study avatar BioFINDER @biofinder_study ·
15 May 2055266597065949252

A big thanks to all authors and collaborators!
@LuLina000147323, @ines_hristovska, @cumplido_irene, @anlijuncn, @RikOssenkoppele, @SebastianPalmqv, @_JakeVogel_, @EStomrud, @NiklasMattsson4

More posts...